Chronic Spontaneous Urticaria
Itch, urticaria activity improve with dupilumab after refractory antihistamine treatment
SAN DIEGO — Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.
Chronic spontaneous urticaria severity impacts disease burden, treatment satisfaction
The severity of a patient’s chronic spontaneous urticaria impacted several outcomes, including quality of life and treatment satisfaction, according to results published in Annals of Allergy, Asthma and Immunology.
Top in allergy/asthma: Passing of Marcus Maurer, MD; briquilimab for chronic urticaria
The allergy and immunology community mourns the loss of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine in Berlin, who is remembered for his excellent teaching and scientific achievements.
Patients with chronic spontaneous urticaria see well-controlled disease with briquilimab
Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 weeks of treatment, with responses as early as week 1, according to an online presentation by Jasper Therapeutics.
Top 10 skin disorder stories of 2024
The year 2024 was important for skin disorders with many innovations and breakthroughs.
FDA accepts resubmission of sBLA for Dupixent for chronic spontaneous urticaria
The FDA has accepted the resubmission of the supplemental biologics license application for Dupixent to treat chronic spontaneous urticaria in adults and children, Regeneron Pharmaceutical and Sanofi announced in a press release.
Chronic spontaneous urticaria symptoms improve with dupilumab through 24 weeks
BOSTON — Patients with chronic spontaneous urticaria experienced significant improvements through 24 weeks with dupilumab, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Chronic spontaneous urticaria symptoms improve in 1 week with remibrutinib
BOSTON — Chronic spontaneous urticaria symptoms improved with 1 week of remibrutinib treatment, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Spontaneous chronic urticaria improvement seen with Dupixent treatment
Patients with chronic spontaneous urticaria experienced a marked improvement with Dupixent treatment, according to phase 3 trial results released by Regeneron.
Options available for patients with urticaria whose omalizumab therapy fails
SAN ANTONIO — Patients with urticaria who do not respond to omalizumab have other options for treatment, David A. Khan, MD, said during the 16th Annual Allergy, Asthma & Immunology CME Conference.